India Glycols consolidated PAT +32% YoY on lower finance costs; segment margins compress

India Glycols' consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 19.39% YoY to ₹2,988.44 Cr and PAT rose 32.18% YoY to ₹96.83 Cr (basic EPS ₹14.45 vs ₹11.83), with NPM expanding to 3.24% from 2.92% a year ago. Sequentially revenue was up 26.63% QoQ and PAT up 11.45% QoQ, but profit growth trailed revenue growth QoQ as NPM slipped from 3.68% in Q4 FY26 — consistent with summer being the seasonally strongest quarter for the Potable Spirits business rather than a step-change in profitability. No analyst consensus or preview for this print turned up in a web search ahead of the company's scheduled August 14, 2026 earnings call, so vsStreet is unknown. The headline PAT growth is driven less by core operations than by two below-the-line items: finance costs fell 43.6% YoY to ₹25.18 Cr from ₹44.68 Cr, saving roughly ₹19.5 Cr and directly reflecting management's stated debt-reduction priority from the Q4 FY26 call; and the JV profit share (Clariant IGL Specialty Chemicals) rose to ₹20.60 Cr from ₹18.62 Cr. Combined segment EBIT grew only 9.2% YoY to ₹140.70 Cr — slower than the 19.4% revenue growth — and consolidated EBITDA margin actually compressed to 5.69% from 6.03% a year ago (7.08% in Q4 FY26). Potable Spirits (74% of revenue, +22.9% YoY) saw its EBIT margin fall to 3.38% from 4.01%, at odds with management's guidance that premiumization would lift margins there; Bio-based Specialities & Performance Chemicals grew revenue 21.1% YoY but EBIT fell 3.7% as margin compressed to 8.64% from 10.87%, only partly bearing out the guided 'significant growth' in value-added chemicals. Bio-Fuel bucked the pattern — revenue fell 7.0% YoY to ₹323.22 Cr but segment EBIT still rose 19.2% to ₹27.03 Cr, a profitability improvement even as volumes softened. Against Q4 FY26 guidance, the debt-reduction/lower-interest-cost commitment is clearly on track and revenue growth in Potable Spirits and Performance Chemicals came through as flagged, but the margin-expansion promise in both segments has not yet shown up at the EBIT line — a 'met on revenue and financing, incomplete on margins' read. This quarter's management changes (Pragya Bhartia Barwale moving to Non-Executive Director; senior personnel transferred to subsidiary IGL Spirits; a new Executive Director & COO appointed at a subsidiary) coincide with the NCLT-sanctioned demerger of the Spirits & Biofuel and Bio Pharma undertakings into separately listed IGL Spirits Limited and Ennature Bio Pharma Limited (order dated July 17, 2026, appointed date April 1, 2026), which the company states has no bearing on this quarter's reported numbers. Standalone PAT of ₹76.59 Cr (EPS ₹11.43) grew a faster 44.9% YoY than consolidated's 32.18%, since standalone excludes the JV share — the two bases diverge by over 3 points here, but the consolidated figure is the primary read.